^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Oral Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The KRAS mutation status and resistance to cetuximab in patients with squamous cell carcinoma of oral cavity.
Published date:
05/28/2020
Excerpt:
In the mC-resistant subgroup, the mtKRAS ratio increased 1.9 times compared to the period before treatment (p = 0.009), while the frequency of mtKRAS increased 3.5 times compared with the mC-sensitive group (p = 0.0045).
DOI:
10.1200/JCO.2020.38.15_suppl.e15514
